The Oncology Institute Inc Stock Price, News & Analysis

The Oncology Institute (TOI) will release its Q4 & full year 2022 financial results after market close on March 9, 2023. A conference call will follow at 5:00 p.m. ET. Investors can participate via phone or by accessing a webcast through the Investor Relations section of TOI's website. TOI, founded in 2007, specializes in value-based cancer care, servicing approximately 1.7 million patients with over 90 clinicians and more than 700 teammates across 50+ locations. The company is focused on advancing oncology with evidence-based care and innovative delivery models.

The Oncology Institute (NASDAQ: TOI) has acquired the practice of Dr. Labib Hashimi in Chino, California, expanding its presence to 42 clinics in the state. This move aims to improve patient access in Los Angeles, Riverside, and San Bernardino Counties. The acquisition is a strategic response to growing demand for TOI's value-based care model, emphasizing quality outcomes and underserved populations. The Chino/Chino Hills Clinic will continue operations seamlessly under its new management, enhancing service provision in the community.

The Oncology Institute (NASDAQ: TOI) is rebranding its clinical research division from Innovative Clinical Research Institute (ICRI) to TOI Clinical Research.

This division will continue managing over 160 clinical trials in oncology, focusing on solid tumors and hematological malignancies.

TOI aims to improve access to the latest treatments and enhance health equity in underserved communities while maintaining its commitment to high-quality patient care and strategic partnerships in the biopharmaceutical industry.

TOI Expands into South Florida

The Oncology Institute (NASDAQ: TOI) has announced its entry into Miami-Dade County by acquiring Hematology/Oncology Associates of Miami. This expansion is part of TOI's strategy to enhance value-based cancer care in Florida. Dr. Roberto Ochoa has been appointed as the Senior Medical Director for the state, emphasizing a commitment to quality care for patients. The South Miami Clinic will continue operations during renovations, with additional locations planned for 2023. TOI aims to serve approximately 1.7 million patients, bolstered by a growing team of over 90 clinicians.

The Oncology Institute (NASDAQ: TOI) reported Q3 2022 financial results, showing a 24.3% revenue growth to $65 million compared to the prior year. Despite this growth, the net loss decreased slightly to $2.7 million. The company expanded its reach with acquisitions and new clinics, increasing clinician count by 27%. A strategic $110 million investment from Deerfield Management was completed to support growth. However, TOI updated its guidance for 2022, expecting revenue between $245 million and $250 million, lower than previous estimates due to acquisition delays.

The Oncology Institute, Inc. (NASDAQ: TOI) announced that CEO Brad Hively and CFO Mihir Shah will speak at the Credit Suisse 31st Annual Healthcare Conference on November 10, 2022. Founded in 2007, TOI is a leading value-based oncology group in the U.S., providing specialized cancer care to about 1.7 million patients through over 50 clinics. The institute employs more than 90 clinicians and focuses on advanced, evidence-based treatment options.

The Oncology Institute (TOI) announced it will release its third quarter financial results on November 9, 2022, after market close. The results will be followed by a conference call at 5:00 p.m. Eastern Time. Investors can access the call via phone or live webcast through the company's Investor Relations website. Founded in 2007, TOI provides value-based oncology care to approximately 1.7 million patients, supported by over 90 clinicians across 50 clinic locations. For further information, visit their official website.

The Oncology Institute (NASDAQ: TOI) is enhancing its presence in value-based oncology care. Executives will attend key conferences, including the Association for Value-Based Cancer Care from October 19-21 in New York, where CEO Brad Hively will address capital markets' impact on cancer care. Other sessions include insights from COO Dr. Matt Miller and Chief Medical Officer Dr. Yale Podnos. Dr. Daniel Virnich will also speak at the Reuters Oncology Conference on October 20. These events reflect TOI's growth and commitment to innovative oncology solutions.

The Oncology Institute announces the appointment of Phil Reger as Chief Information Officer and Cristina Green as Vice President of Clinical Research. Reger, with 25 years of IT experience including healthcare, will lead technology initiatives to support the company's growth. Green, boasting over 24 years in clinical research, will enhance access to clinical trials for patients. CEO Brad Hively emphasized the importance of their leadership in advancing TOI's focus on research and health equity. TOI aims to deliver specialized, value-based cancer care across the U.S.